RECONSTRUCTION OF ANTILEPROSY DRUG DEPLETED COMPLEMENT HEMOLYTIC-ACTIVITY BY ADDITION OF ZYMOSAN-TREATED SERA (A SOURCE OF C142) AND CRATEDTA (A SOURCE OF C3-C9)

被引:1
作者
KASHYAP, A
SAHA, K
SEHGAL, VN
机构
[1] VALLABH BHAI PATEL CHEST INST,DEPT IMMUNOL & MICROBIOL,POB 2101,DELHI 110007,INDIA
[2] LADY HARDINGS MED COLL,DEPT DERMATOL & VENEREOL,NEW DELHI 110001,INDIA
[3] ASSOCIATED SK & SKC HOSP,NEW DELHI 110001,INDIA
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1992年 / 14卷 / 08期
关键词
D O I
10.1016/0192-0561(92)90012-A
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This paper describes the mechanism of in vitro interaction of human serum complement system with anti-leprosy drugs (dapsone and clofazimine) and anti-lepra reaction drugs such as chloroquine. These drugs could inhibit the complement-mediated lysis of erythrocytes both via direct and alternative pathways, but only at hypertherapeutic doses. Attempts were made to restore the drug depleted complement-mediated lysis of erythrocytes by adding zymosan-treated guinea-pig sera (a source of C142) and also by adding C(rat)-EDTA sera (a source of C3 - C9). Destroyed complement-mediated haemolytic activity by dapsone could be restored by early complement (C142) components, while complement-mediated haemolytic activity blocked by clofazimine could be regenerated by adding both late (C3 - C9) and early (C142) complement component. However, chloroquine-mediated inhibition of the complement-mediated haemolysis activity could not be appreciably restored by adding both early and late complement reagents.
引用
收藏
页码:1409 / 1414
页数:6
相关论文
共 16 条
[1]   INVITRO INHIBITION OF THE CLASSICAL PATHWAY OF HUMAN-COMPLEMENT BY POLYMYXIN-B [J].
ASGHAR, SS ;
BOOT, T ;
VANDERHELM, HJ .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (18) :2927-2930
[2]  
AUTERI A, 1988, INT J TISSUE REACT, V10, P217
[3]  
CAMPBELL DH, 1964, METHOD IMMUNOL, P175
[4]  
CHAKRABARTY AK, 1988, INT J LEPROSY, V56, P559
[5]   EFFECTS OF CHLOROQUINE ON THE SERUM COMPLEMENT-SYSTEM [J].
CHAKRABARTY, AK ;
SAHA, K ;
CHOPRA, S ;
SEN, P .
IMMUNOPHARMACOLOGY, 1985, 10 (02) :111-118
[6]  
DIPERRI T, 1973, ARCH INT PHARMACOD T, V203, P23
[7]  
DIPERRI T, 1982, INT J TISSUE REACT, V4, P9
[8]  
FING JSC, 1972, CLIN EXP IMMUNOL, V10, P127
[9]   ANTI-COMPLEMENT EFFECTS OF 2 ANTIINFLAMMATORY AGENTS - NIFLUMIC AND FLUFENAMIC ACIDS [J].
HARRITY, TW ;
GOLDLUST, MB .
BIOCHEMICAL PHARMACOLOGY, 1974, 23 (22) :3107-3120
[10]   ANTILEPROSY DRUGS INHIBIT THE COMPLEMENT-MEDIATED SOLUBILIZATION OF PREFORMED IMMUNE-COMPLEXES INVITRO [J].
KASHYAP, A ;
SEHGAL, VN ;
SAHU, A ;
SAHA, K .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1992, 14 (02) :269-273